-+ 0.00%
-+ 0.00%
-+ 0.00%

ORYZON RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE THE HOPE-2 PHASE II STUDY OF VAFIDEMSTAT FOR THE TREATMENT OF PHELAN-MCDERMID SYNDROME (PMS)

Reuters·09/28/2026 12:02:33